(Photo Courtesy: www.itpro.co.uk)
AstraZeneca terminated its collaborative research and license agreement with Targacept, a North Carolina-based, US biopharmaceutical company.
The collaboration started in 2005, and is now terminated after nearly 9 years.
The termination becomes effective 90 days after October 8, 2014.
The decision will end the collaboration on TC-6683 compound.
All the rights and licenses on this compound will be returned to Targacept.